HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

James Cheng-Chung Wei Selected Research

Interleukin-17 (Interleukin 17)

12/2018Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


James Cheng-Chung Wei Research Topics

Disease

3Ankylosing Spondylitis
11/2022 - 12/2016
3Infections
12/2021 - 12/2018
2COVID-19
10/2023 - 01/2022
2Type 2 Diabetes Mellitus (MODY)
06/2023 - 07/2021
2Disease Progression
01/2023 - 08/2021
2Inflammation (Inflammations)
11/2022 - 01/2016
1Parkinson Disease (Parkinson's Disease)
01/2024
1Hepatic Encephalopathy
06/2023
1Liver Failure
06/2023
1Brain Diseases (Brain Disorder)
06/2023
1Liver Cirrhosis (Hepatic Cirrhosis)
06/2023
1Fibrosis (Cirrhosis)
06/2023
1Alzheimer Disease (Alzheimer's Disease)
01/2023
1Osteoarthritis
01/2023
1Genetic Predisposition to Disease (Genetic Predisposition)
11/2022
1Atherosclerosis
11/2022
1Cardiovascular Diseases (Cardiovascular Disease)
11/2022
1Syphilis
10/2022
1Ischemic Stroke
10/2022
1Papillomavirus Infections
01/2022
1Salmonella Infections (Salmonellosis)
12/2021
1Dementia (Dementias)
10/2021
1Gout
08/2021
1Urolithiasis
08/2021
1Rheumatoid Arthritis
12/2020
1Axial Spondyloarthritis
12/2018
1Candidiasis (Moniliasis)
12/2018
1Crohn Disease (Crohn's Disease)
12/2018
1Sacroiliitis
12/2018
1Fatigue
12/2016
1Chronic Disease (Chronic Diseases)
12/2016
1Neuroinflammatory Diseases
01/2016

Drug/Important Bio-Agent (IBA)

2Biomarkers (Surrogate Marker)IBA
01/2023 - 11/2022
2CytokinesIBA
01/2023 - 01/2016
1Caffeine (No Doz)FDA LinkGeneric
01/2024
1Retinaldehyde (Retinal)IBA
10/2023
1Glucagon-Like Peptide-1 Receptor AgonistsIBA
06/2023
1Glucagon-Like Peptide-1 ReceptorIBA
06/2023
1Glucagon-Like Peptide 1 (GLP 1)IBA
06/2023
1Vitamin DFDA LinkGeneric
01/2023
1Circular RNAIBA
01/2023
1CollagenIBA
01/2023
1LipidsIBA
11/2022
1Tumor Necrosis Factor InhibitorsIBA
11/2022
1Anti-Bacterial Agents (Antibiotics)IBA
10/2022
1VaccinesIBA
01/2022
125-hydroxyvitamin DIBA
01/2022
1Xanthine OxidaseIBA
08/2021
1Uricosuric AgentsIBA
08/2021
1Uric Acid (Urate)IBA
08/2021
1Hypoglycemic Agents (Hypoglycemics)IBA
07/2021
1Metformin (Glucophage)FDA LinkGeneric
07/2021
1Dipeptidyl-Peptidase IV InhibitorsIBA
07/2021
1Monoclonal AntibodiesIBA
12/2018
1Antirheumatic Agents (DMARD)IBA
12/2018
1Adalimumab (Humira)FDA Link
12/2018
1Interleukin-17 (Interleukin 17)IBA
12/2018
1ixekizumabIBA
12/2018
1secukinumabIBA
12/2016
1AntioxidantsIBA
01/2016
1PolyphenolsIBA
01/2016
1Amyloid (Amyloid Fibrils)IBA
01/2016
1TeaIBA
01/2016
1NeurotoxinsIBA
01/2016
1epigallocatechin gallate (epigallocatechin-3-gallate)IBA
01/2016

Therapy/Procedure

3Therapeutics
08/2021 - 12/2016
1Cholecystectomy
12/2021
1Chinese Traditional Medicine (Traditional Chinese Medicine)
10/2021
1Arthroplasty
12/2020